Impact of CYP4F2 rs2108622 on the Stable Warfarin Dose in an Admixed Patient Cohort

There is controversy regarding the association between the CYP4F2 rs2108622 (V33M) polymorphism and warfarin dose requirement in white patients, and there are no data for nonwhite populations. We observed no association in self‐identified white, black, or “intermediate” Brazilian patients (n = 370)....

Full description

Saved in:
Bibliographic Details
Published in:Clinical pharmacology and therapeutics 2010-04, Vol.87 (4), p.417-420
Main Authors: Perini, J A, Struchiner, C J, Silva‐Assunção, E, Suarez‐Kurtz, G
Format: Article
Language:English
Subjects:
African Continental Ancestry Group - genetics
Algorithms
Anticoagulants - administration & dosage
Biological and medical sciences
Brazil
Cohort Studies
Continental Population Groups - genetics
Cytochrome P-450 Enzyme System - genetics
Cytochrome P450 Family 4
Dose-Response Relationship, Drug
European Continental Ancestry Group - genetics
Humans
Medical sciences
Pharmacology. Drug treatments
Polymorphism, Genetic
Retrospective Studies
Warfarin - administration & dosage
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:There is controversy regarding the association between the CYP4F2 rs2108622 (V33M) polymorphism and warfarin dose requirement in white patients, and there are no data for nonwhite populations. We observed no association in self‐identified white, black, or “intermediate” Brazilian patients (n = 370). The addition of the rs2108622 genotype as a variable has only a marginal effect on the predictive power of a warfarin dosing algorithm derived from this patient cohort. We conclude that prospective CYP4F2 genotyping is not justified in Brazilians who are potential candidates for warfarin therapy. Clinical Pharmacology & Therapeutics (2010) 87 4, 417–420. doi:10.1038/clpt.2009.307
ISSN:0009-9236
1532-6535
DOI:10.1038/clpt.2009.307